What is Adocia S.A. (ADOIF)?

Adocia S.A. (ADOIF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ADOIF?

The current price of ADOIF is $8.87. Prices are updated in real time on Stocks360.

What is ADOIF's price-to-earnings (PE) ratio?

ADOIF's trailing twelve-month PE ratio is -2.46, based on current price and earnings per share data available on Stocks360.

What is ADOIF's market capitalization?

ADOIF's market capitalization is $103,664,732.00, placing it in the small-cap tier.

Adocia S.A. (ADOIF)

Stock analysis · OTC · Healthcare · Biotechnology

$8.87

Market Cap

$103.66M

PE (TTM)

-2.46

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.72

Day Range

$8.87 – $8.87

52-wk Range

$8.87 – $8.87

Avg Volume

N/A

Volume

1.00K

Adocia S.A. (ADOIF) is a publicly traded company in the Healthcare sector. Latest price: $8.87. Market cap $103.66M. Trailing PE -2.46. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Adocia S.A.

Adocia S.A., a biotechnology firm founded in Lyon, France, in 2005, operates at the clinical stage, focusing its research and development efforts on optimizing existing therapeutic proteins and peptides for the management of diabetes and various other metabolic conditions. The company's core innovation lies in its proprietary BioChaperone technological platform, specifically engineered to enhance the effectiveness and performance of therapeutic proteins. Adocia's product pipeline currently in clinical trials features several advanced insulin formulations. These include BioChaperone Lispro U100 and U200, which offer ultra-rapid action derived from rapid insulin lispro. Other notable candidates are BioChaperone Combo, a combination of both long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; BioChaperone Glucagon, an aqueous human glucagon formulation for treating low blood sugar; and M1Pram, a product based on a metabolite of insulin glargine and pramlintide. In addition to its clinical assets, Adocia boasts a strong preclinical pipeline. This includes bi-hormonal treatments such as BioChaperone AsPram, w…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.46×
P/S (TTM)	64.09×
P/B	-4.05×
P/FCF (TTM)	-4.72×
EV / EBITDA	-5.78×
EV / Sales	77.46×
Earnings Yield	-40.71%
Free Cash Flow Yield	-21.17%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$111.86M
Revenue (TTM)	$1.44M
Net Income (TTM)	-$37.68M
Free Cash Flow (TTM)	-$17.35M
Net Debt	$19.32M
Working Capital	-$1.67M
Gross Margin	12.47%
Operating Margin	-1341.14%
Net Margin	-1575.76%
Return on Equity	608.31%
Return on Invested Capital	-86.08%